Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO4989991 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | PLACEBO_COMPARATOR | - |
| 4 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Subcutaneous repeated dose |
| RO4989991 | DRUG | Subcutaneous repeated dose |
Inclusion Criteria: * Adult patients, 18-65 years of age, inclusively * A history of allergic rhinitis diagnosed by a physician, but otherwise healthy * A positive skin prick test to at least one standardized allergen at screening * A body mass index (BMI) between 18 and 32 kg/m2, inclusively Excl...
RO4989991 is an investigational small molecule being studied for the treatment of asthma. It is being developed by Roche Holding AG (ticker: RHHBY) and is currently in Phase 1 clinical development.
The specific molecular target of RO4989991 has not been disclosed in available information. It is a small molecule being investigated for its potential therapeutic effect in asthma.
RO4989991 is being developed by Roche Holding AG, a multinational healthcare company. Roche's stock is traded under the ticker RHHBY on the OTC market.
RO4989991 is in Phase 1 clinical development. It has completed one Phase 1 trial, and there are no active trials currently ongoing.
RO4989991 has been studied in one clinical trial, identified as NCT01152619. This was a Phase 1, randomized, double-blind, placebo-controlled study in patients with allergic rhinitis, conducted in the United States. The trial has been completed.
RO4989991 is not FDA approved. It is an investigational drug that has completed Phase 1 clinical trials but has not yet received regulatory approval for any indication.